The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
暂无分享,去创建一个
[1] T. Yamamura,et al. Gut microbiota-dependent CCR9+CD4+ T cells are altered in secondary progressive multiple sclerosis , 2019, Brain : a journal of neurology.
[2] G. Weinstock,et al. Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota. , 2018, Cell metabolism.
[3] David H. Miller,et al. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop , 2018, Multiple sclerosis.
[4] X. Montalban,et al. Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. , 2017, Autoimmunity reviews.
[5] A. Mangalam,et al. Gut microbiome in multiple sclerosis: The players involved and the roles they play , 2017, Gut microbes.
[6] V. Martinelli,et al. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis , 2017, Science Advances.
[7] C. Surawicz,et al. Fecal Microbiota Transplantation. , 2017, Gastroenterology clinics of North America.
[8] J. Machan,et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection , 2016, Annals of Internal Medicine.
[9] Tingting Zhang,et al. Excess Body Weight during Childhood and Adolescence Is Associated with the Risk of Multiple Sclerosis: A Meta-Analysis , 2016, Neuroepidemiology.
[10] Justine W. Debelius,et al. Gut dysbiosis is a feature of MS and it is characterized by bacteria able to regulate lymphocyte differentiation in vitro , 2016 .
[11] Bangmao Wang,et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation , 2016, PloS one.
[12] Laura M Cox,et al. Alterations of the human gut microbiome in multiple sclerosis , 2016, Nature Communications.
[13] Krishna R. Kalari,et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls , 2016, Scientific Reports.
[14] E. Waubant,et al. Gut microbiota composition and relapse risk in pediatric MS: A pilot study , 2016, Journal of the Neurological Sciences.
[15] Young-Seok Cho,et al. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives , 2016, Clinical endoscopy.
[16] P. Vitaglione,et al. Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study , 2016, Experimental biology and medicine.
[17] R. Gold,et al. Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine. , 2015, Immunity.
[18] M. Hattori,et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters , 2015, PloS one.
[19] Manuel A. Friese,et al. Immunopathology of multiple sclerosis , 2015, Nature Reviews Immunology.
[20] A. Venkatesan,et al. Gut Microbiota in Multiple Sclerosis , 2015, Journal of Investigative Medicine.
[21] N. Arbour,et al. Multiple Sclerosis and T Lymphocytes: An Entangled Story , 2015, Journal of Neuroimmune Pharmacology.
[22] T. Wilt,et al. Fecal Microbiota Transplantation for Clostridium difficile Infection , 2015, Annals of Internal Medicine.
[23] Xiaocang Cao,et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. , 2015, World journal of gastroenterology.
[24] M. Holick. Vitamin D and brain health: the need for vitamin D supplementation and sensible sun exposure , 2015, Journal of internal medicine.
[25] M. Carrithers. Update on disease-modifying treatments for multiple sclerosis. , 2014, Clinical therapeutics.
[26] D. Rubin,et al. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Journal of Crohn's & colitis.
[27] K. Berer,et al. Microbial view of central nervous system autoimmunity , 2014, FEBS letters.
[28] G. Russell,et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. , 2014, JAMA.
[29] P. Bhargava,et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. , 2014, Contemporary clinical trials.
[30] P. Bhargava,et al. Gut Microbiome and Multiple Sclerosis , 2014, Current Neurology and Neuroscience Reports.
[31] D. Jarrossay,et al. The Oral Commensal Streptococcus mitis Shows a Mixed Memory Th Cell Signature That Is Similar to and Cross-Reactive with Streptococcus pneumoniae , 2014, PloS one.
[32] M. Hattori,et al. Foxp3(+) T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. , 2014, Immunity.
[33] R. Schmitz,et al. The Intestinal Archaea Methanosphaera stadtmanae and Methanobrevibacter smithii Activate Human Dendritic Cells , 2014, PloS one.
[34] M. Mellow,et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients , 2014, The American Journal of Gastroenterology.
[35] D. Agrawal,et al. Vitamin D and inflammatory diseases , 2014, Journal of inflammation research.
[36] A. Bar-Or,et al. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.
[37] L. Steinman. Immunology of relapse and remission in multiple sclerosis. , 2014, Annual review of immunology.
[38] J. Oksenberg. Decoding multiple sclerosis: an update on genomics and future directions , 2013, Expert review of neurotherapeutics.
[39] A. Ascherio. Environmental factors in multiple sclerosis , 2013, Expert review of neurotherapeutics.
[40] A. Rudensky,et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.
[41] M. Tomita,et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells , 2013, Nature.
[42] Bing Xia,et al. Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease , 2013, Journal of Clinical Microbiology.
[43] X. Yao,et al. Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis , 2013, Clinical & translational immunology.
[44] N. Jantaratnotai,et al. Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia. , 2013, International immunopharmacology.
[45] R. Klopfleisch,et al. Commensal Akkermansia muciniphila Exacerbates Gut Inflammation in Salmonella Typhimurium-Infected Gnotobiotic Mice , 2013, PloS one.
[46] L. Brandt,et al. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. , 2013, Gastrointestinal endoscopy.
[47] M. Hattori,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.
[48] I. Lavi,et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties , 2013, BMC Neurology.
[49] Hanne F. Harbo,et al. Sex and gender issues in multiple sclerosis , 2013, Therapeutic advances in neurological disorders.
[50] Robert Weissert. The Immune Pathogenesis of Multiple Sclerosis , 2013, Journal of Neuroimmune Pharmacology.
[51] M. Vaisberg,et al. Vitamin D3 Induces IDO+ Tolerogenic DCs and Enhances Treg, Reducing the Severity of EAE , 2013, CNS neuroscience & therapeutics.
[52] K. Raza,et al. Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses , 2012, The Journal of Immunology.
[53] Casey T. Weaver,et al. Reciprocal interactions of the intestinal microbiota and immune system , 2012, Nature.
[54] K. Brown,et al. Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease , 2012, Nutrients.
[55] J. H. Kim,et al. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis , 2012, Infection.
[56] A. Macpherson,et al. Interactions Between the Microbiota and the Immune System , 2012, Science.
[57] A. Khoruts,et al. Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.
[58] K. Rhodes,et al. Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway , 2012, Journal of Pharmacology and Experimental Therapeutics.
[59] Richard Hansen,et al. IBD—what role do Proteobacteria play? , 2012, Nature Reviews Gastroenterology &Hepatology.
[60] F. Paul,et al. Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial , 2012, Trials.
[61] F. Barkhof,et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial , 2011, Journal of the Neurological Sciences.
[62] J. Bakken,et al. Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[63] Michelino Di Rosa,et al. Vitamin D3: a helpful immuno‐modulator , 2011, Immunology.
[64] W. D. de Vos,et al. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila , 2011, Front. Microbio..
[65] F. Jadidi-Niaragh,et al. Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis , 2011, Scandinavian journal of immunology.
[66] L. Blizzard,et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.
[67] K. Walsh,et al. Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.
[68] K. Honda,et al. Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species , 2011, Science.
[69] N. Tubridy,et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis , 2010, Clinical and experimental immunology.
[70] L. Brandt,et al. Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy: A Case Series of 12 Patients , 2010, Journal of clinical gastroenterology.
[71] A. Ascherio,et al. Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.
[72] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[73] S. Dhib-jalbut,et al. Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.
[74] A. Schwiertz,et al. Microbiota and SCFA in Lean and Overweight Healthy Subjects , 2010, Obesity.
[75] B. Roe,et al. A core gut microbiome in obese and lean twins , 2008, Nature.
[76] V. De Rosa,et al. The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? , 2008, Journal of leukocyte biology.
[77] L. Piccio,et al. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis , 2008, Journal of leukocyte biology.
[78] R. Wilson,et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut , 2007, Proceedings of the National Academy of Sciences.
[79] M. Hutchinson. Natalizumab: A new treatment for relapsing remitting multiple sclerosis , 2007, Therapeutics and clinical risk management.
[80] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[81] E. Frohman,et al. Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.
[82] V. De Rosa,et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[83] Nitin J. Karandikar,et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. , 2004, Blood.
[84] G. Matarese,et al. The weight of leptin in immunity , 2004, Nature Reviews Immunology.
[85] A. Aljada,et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. , 2003, Diabetes.
[86] J. Bakken,et al. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[87] L. Brandt,et al. Treatment of recurrent Clostridium difficile–associated diarrhea by administration of donated stool directly through a colonoscope , 2000, American Journal of Gastroenterology.
[88] Stephen R. Bloom,et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression , 1998, Nature.
[89] E. Ravussin,et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.
[90] T. Ziemssen,et al. Glatiramer acetate: mechanisms of action in multiple sclerosis. , 2007, International review of neurobiology.
[91] M. Rovaris,et al. Mitoxantrone for multiple sclerosis. , 2005, The Cochrane database of systematic reviews.